February 3-5, 2026 | Boston, MA

www.proteomic-drug-discovery.com

REGISTER BY FRIDAY, OCTOBER 31 TO SAVE UP TO $900

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

2nd Annual

Proteomics Based Drug Discovery Summit

Leverage the Power of the Proteome to Drug the Undruggable

Utilize High-Throughput Proteomics to Accelerate Hit Screening, Target Validation & Lead Optimization for Smarter & Faster Drug Development

Expert Speakers Include:

Harris Bell-Temin
Director, Proteomics
Johnson & Johnson

Stella Ritorto
Senior Director & Head of Mass Spectrometry
ProFound Therapeutics

Karsten Krug
Director & Head of Bioinformatics
Frontier Medicines

Emanuela Tschudy-Milani
Vice President, Technology
DISCO Pharmaceuticals

John Corradi
Director, Bioinformatics & Proteomics
Arvinas

Satya Saxena
Director, Global Proteomics
Eisai

Proud to Partner With:

SYNCELL

+1 617 455 4188 | info@hansonwade.com

www.proteomic-drug-discovery.com | The UnDruggable Series

hansonwade

Welcome to the 2nd Proteomics Based Drug Discovery Summit

Proteomics Based Drug Discovery Summit

February 3-5, 2026 | Boston, MA

In 2025 alone, **Novartis** has committed $750M to **ProFound Therapeutics** to discover new proteins for cardiovascular drug development, and **Illumina** has acquired SomaLogic for $350M to expand its proteomic capabilities. This reflects proteomics' growing strategic value in identifying better drug candidates faster.

Returning for its 2nd year, the **Proteomics Based Drug Discovery Summit** is **the only industry-focused event dedicated to embedding proteomics across the entire drug discovery pipeline**. From elucidating disease mechanisms and validating new targets to hit identification and candidate optimization, this is your chance to harness proteomics' potential to unlock the proteome and drug the undruggable.

Get ahead of the curve with exclusive data and case studies, directly from industry leaders, to help you:

- **Prioritize the most promising targets faster** by using proteomics to optimize compound screening and unravel disease signaling pathways to illuminate the proteome
- **Increase data robustness and experimental throughput** by overcoming bottlenecks in sample preparation, assay design and data analysis to streamline proteomics workflows
- **Select the right instrumentation for your workflow** with case studies of next-generation mass spectrometry, chemoproteomics, single-cell and spatial proteomics methodologies
- **Maximize efficiency of drug discovery no matter the modality** by tailoring your proteomic strategy for your drug type, whether covalency, molecular glues, degraders or bispecifics

Join 70+ Directors, Vice Presidents, and experts in **Proteomics**, **Chemical Biology**, **Mass Spectrometry** and **Drug Discovery** to tap into the full competitive advantage of protein-level insight, enabling you to progress the most promising targets and strategically expand your therapeutic pipeline.

What's On in 2026?

70+ Attendees

24+ Expert Speakers

7+ Hours of Networking

2 Interactive Workshops

1 Scientific Poster Session

Key Benefits of Attending

Map the proteome accurately with high-sensitivity, high-throughput proteomics, optimized platforms, and automated sample processing, with updates from **Eisai**, **Johnson & Johnson** & **AstraZeneca**.

Optimize your proteomics workflow with innovative approaches including spatial proteomics, single-cell analysis and immunopeptidomics with **Aethon Therapeutics**, **Slavov Lab** & **DISCO Pharmaceuticals**.

Define gold standard data analysis methodologies to generate meaningful conclusions from large data sets, while ensuring patient data is managed securely with insights from **Acrivon Therapeutics** & **ProFound Therapeutics**.

Illuminate post-translational modifications with sensitive proteomics platforms to capture proteome dynamics and decode disease signatures to guide therapeutic strategy, with **Blueprint Medicines** & **Merck**.

Unlock optimized hit screening and triaging strategies across a range of modalities using unique insights from chemoproteomics platforms to maximize efficiency of lead development with **Dunad Therapeutics**, **Frontier Medicines** & **Novartis**.

+1 617 455 4188 info@hansonwade.com
www.proteomic-drug-discovery.com The UnDruggable Series
hansonwade

What's New For 2026?

Proteomics Based Drug Discovery Summit
February 3-5, 2026 | Boston, MA

Key Sessions not to Miss

Facilitating Time & Cost-Effective Proteomic Analysis with High Throughput Mass Spectrometry Capabilities to Support Drug Discovery at Scale

Harris Bell-Temin, Director, Proteomics, **Johnson & Johnson**

1

Quantitative Post-Translational Modifications-Omics to Support Drug Discovery

Benjamin Ruprecht, Director, Proteomics, **Blueprint Medicines**

2

Implementing Multi-Omics Into Workflows to Paint a Holistic Picture of Health, Contextualize Proteomics Insights & Inform Drug Discovery

Joel Chick, Vice President, Proteomics Discovery, **RyboDyn**

3

Quantitative Immunopeptidomics Drives Target Discovery & Rational Antibody Design for T Cell Engagers

Lauren Stopfer, Executive Director of Proteomics & Innovation, **Aethon Therapeutics**

4

Standardizing Proteomics Data Analysis & Selecting Appropriate Frameworks to Ensure Reproducibility & Statistical Accuracy

Liang Xue, Director, Bioinformatics, **Pfizer**

5

New Companies for 2026 Include:

Acrivon Therapeutics, RYBODYN, blueprint MEDICINES, MERCK, ARVINAS, PROFOUND THERAPEUTICS, Northeastern University, J&J, FRONTIER MEDICINES, Dana-Farber Cancer Institute, DISCO PHARMACEUTICALS, Aquinnah, DUNAD therapeutics, Eisai, aethon, LIGHT HORSE THERAPEUTICS, Pfizer, Cellarity, Beth Israel Deaconess Medical Center, REGENERON

Featured Modalities



Targeted Protein Degradation / Molecular Glues

Covalency

Antibodies

Small Molecules

Gene Therapy

+1 617 455 4188 info@hansonwade.com
www.proteomic-drug-discovery.com The UnDruggable Series
hansonwade

Your Expert Speakers

Large Pharma Decision-Makers

An Chi
Senior Director
Merck

Ansgar Brock
Associate Director
Novartis

Harris Bell-Temin
Director, Proteomics
Johnson & Johnson

Liang Xue
Director, Bioinformatics
Pfizer

Monica Lane
Associate Director, Genomic Medicines & Bioanalytics Characterization
Sanofi

Satya Saxena
Director, Global Proteomics
Eisai

Biotech Decision-Makers

Antony Burton
Associate Director, Chemical Biology & Proteomics
Dunad Therapeutics

Benjamin Ruprecht
Director, Proteomics
Blueprint Medicines

Christoph Schrader
Associate Director
Immatics

Emanuela Tschudy-Milani
Vice President, Technology
DISCO Pharmaceuticals

Joel Chick
Vice President, Proteomics Discovery
RyboDyn

John Corradi
Director Bioinformatics & Proteomics
Arvinas

Joon Jung
Vice President & Head of Data Science
Acrivon Therapeutics

Karsten Krug
Director & Head of Bioinformatics
Frontier Medicines

Landon Whitby
Director, Chemical Biology & Proteomics
Light Horse Therapeutics

Lauren Stopfer
Executive Director, Proteomics & Innovation
Aethon Therapeutics

Mauricio Cortes
Senior Director, Head of Discovery Science
Cellarity

Stella Ritorto
Senior Director & Head of Mass Spectrometry
ProFound Therapeutics

Technical Experts

Robert Salzler
Bioanalytical, Biomarker Technologies & Immunopeptidomics Professional
Regeneron

Uthpala Seneviratne
Associate Principal Scientist
AstraZeneca

Morgan Stykel
Senior Scientist
Aquinnah Pharmaceuticals

Academic KOLs & Leading Clinicians

Nikolai Slavov
Professor
Northeastern University

Michael Roehrl
Chair, Department of Pathology
Beth Israel Deaconess Medical Center

Katherine Donovan
Managing Director, Fischer Labs
Dana-Farber Cancer Institute

Pre-Conference Workshop Day
Tuesday, February 3, 2026

Check In & Light Breakfast — 8.00

Workshop A — 9.00

Optimizing & Automating Sample Processing & Working Effectively With Challenging Samples to Enable Scalable, High Throughput Proteomics Across Drug Discovery Pipelines

Proteomics analysis is driven by sensitive and fast instrumentation, but sample preparation remains a critical bottleneck, especially when working with limited or low-quality data. To fully realize the potential of scalable proteomics for drug discovery, it's crucial that sample preparation workflows are accelerated and optimized.

This workshop will gather experts to discuss how to:

- Transition to scalable, automated sample processing with plate-based formats, minimizing hands-on steps, accounting for variation in sample collection, and adopting automation tools
- Overcome poor sample quality with optimized protocols for low-abundance samples, effective enrichment strategies, and methods to reduce protein loss during preparation
- Uphold quality control standards during assay development, sample collection, processing, and storage to maintain sample integrity and facilitate reproducible proteomics analysis

Workshop Leaders

Uthpala Senevviratne
Associate Principal Scientist
AstraZeneca
Targeted Protein Degradation

Monica Lane
Associate Director, Genomic Medicines & Bioanalytics Characterization
Sanofi
Gene Therapy

Lunch Break & Networking — 12.00

Workshop B — 1.00

Implementing Multi-Omics Into Drug Discovery Workflows to Paint a Holistic Picture of Health, Contextualize Proteomics Insights & Make Well-Informed Drug Discovery Decisions

Whilst proteomics has the potential to reveal the workings of the proteome and demystify disease signalling pathways, part of the story is still missing. Combining genomics, transcriptomics, and metabolomics insights to contextualize proteomics is vital to better understand pathology and guide therapeutic discovery.

This workshop will gather experts to discuss how to:

- Effectively harmonize and integrate genomics, transcriptomics, and metabolomics data to bolster understanding of proteomics and generate a more holistic view of pathology and therapeutic response
- Employ innovative computational and AI tools to streamline multi-omics workflows and maximize time and cost-efficiency of large-scale data analysis
- Apply multi-omics across drug discovery, from deconvoluting disease pathways and identifying novel targets to validating biomarkers and optimizing hit identification

Workshop Leaders

Joel Chick
Vice President, Proteomics Discovery
RyboDyn

Mauricio Cortes
Senior Director, Head of Discovery Science
Cellarity

End Pre-Conference Workshop Day — 4.00

Conference Day One
Wednesday, February 4, 2026

7.00 **Check In & Light Breakfast**

An Chi
Senior Director
Merck

7.50 **Chair's Opening Remarks**

Optimizing Proteomics Workflows With High Throughput Methodologies Including Mass Spectrometry & Beyond to Enable Protein Analysis at Scale

Harris Bell-Temin
Director, Proteomics
Johnson & Johnson

8.00 **Developing Highly Sensitive, High Throughput Methodologies to Perform Time & Cost-Effective Proteomics Analysis to Support Drug Discovery at Scale**

- Achieving proteomics workflows at an unprecedented scale with optimized analysis methodologies
- Balancing coverage, throughput, and sensitivity of proteomic platforms to accurately analyze the proteome, including low-abundance proteins
- Exploring data showing how proteomics can transform drug discovery and unlock otherwise undruggable targets

Uthpala Seneviratne
Associate Principal Scientist
AstraZeneca
Targeted Protein Degradation

8.30 **Facilitating Efficient Proteomic Analysis With High Throughput Mass Spectrometry Capabilities to Power Drug Discovery Pipelines**

- Evaluating automation, mass spectrometry instruments, and selecting appropriate technologies based on project demands, cost, and internal capabilities
- Achieving optimal levels of throughput and sensitivity to meet project demands
- Reviewing data showing the unique benefit of implementing high-throughput mass spectrometry-based proteomics for degrader profiling in the early stage of drug discovery

Landon Whitby
Director, Chemical Biology & Proteomics
Light Horse Therapeutics
Gene Therapy

9.00 **Optimizing Scalable Proteomics Techniques for Efficient Target Deconvolution & Small Molecule Drug Discovery**

- Developing workflows to enable high throughput chemoproteomic analysis with enhanced efficiency
- Strategically optimizing sensitivity, coverage, and throughput to detect a full range of proteins, including those in low abundance
- Evidence to show how proteomics accelerates drug discovery and unlocks previously inaccessible targets

9.30 **Morning Break & Speed Networking**
Network with your peers on this exclusive session to exchange your ideas and generating meaningful industry connections and collaborations with other leaders in the proteomics field

Leveraging the Power of Immunopeptidomics to Guide the Discovery of Efficacious, Safe Therapies

10.30 **Session Reserved for Syncell**

Lauren Stopfer
Executive Director of Proteomics & Innovation
Aethon Therapeutics
Antibodies

11.00 **Quantitative Immunopeptidomics Drives Target Discovery & Rational Antibody Design for T Cell Engagers**

- Exploring how high-sensitivity, targeted immunopeptidomics enable direct detection and detailed characterization of drug-modified (haptenated) peptide–MHC complexes, informing the rational design of bispecific T cell engagers with cross-HLA reactivity
- Outlining how the quantitative profiling of amplified MHC-I targets defines the therapeutic window and guides engineering of T cell engagers against canonical, mutation-agnostic epitopes such as pan-KRAS amplification
- Integrating immunoproteomics-driven target validation with antibody engineering to accelerate the development of next-generation T cell engagers, exemplified by programs targeting mutant KRAS, KRAS amplification, and p53 mutants

Conference Day One
Wednesday, February 4, 2026

Christoph Schraeder
Associate Director
Immatics
Bispecifics

11.30 **A Multi-Omics Platform for Comprehensive pHLA Target Discovery & Validation**

- Leveraging immunopeptidomics to profile and measure cell surface proteins that guide therapeutic decision-making
- Harnessing immunopeptidomics insights to discover and confirm new peptide targets for antibody therapies
- Tackling issues of low-abundance targets and assay sensitivity through cutting-edge technologies and instruments

Satya Saxena
Director of Global Proteomics
Eisai

12.00 **Combining Mass Spectrometry & Alternative Proteomics Platforms to Achieve Optimized Coverage & Throughput for Rapid, Comprehensive Proteomic Analysis**

- Demonstrating the benefits of utilizing mass spectrometry and other proteomics platforms, drawing on the advantages of multiple technologies to unlock greater insights
- Allocating budgets and managing resources effectively to strategically leverage multiple proteomics platforms to achieve maximum insights from patient data
- Deep diving into data from a drug discovery breakthrough made possible with proteomics

Robert Salzler
Bioanalytical, Biomarker Technologies & Immunopeptidomics Professional
Regeneron

12.30 **Increasing Understanding of the Immune System With Immunopeptidomics to Guide the Discovery of Efficacious, Safe Immunotherapies**

- Applying immunopeptidomics to detect and quantify cell surface proteins to inform therapeutic strategy
- Using immunopeptidomics data to identify and validate novel peptide targets for immunotherapies, vaccines and beyond
- Overcoming challenges in low abundance and limited assay sensitivity with advanced technology and AI capabilities

1.00 **Lunch Break & Networking**

Exploring Innovative Methodologies Across Spatial Proteomics & Single Cell Analysis to Unlock Novel Biomedical Insights

Emanuela Tschudy-Milani
Vice President, Technology
DISCO Pharmaceuticals
Antibodies

2.00 **Protein Nanoscale Organization: Unlocking Surfaceomes to Power Next-Generation Therapeutics**

- Introducing DISCOtech: DISCO's proprietary surfaceome proteomics platform and workflow to systematically map nanoscale organizations on the cell-surface proteins across tumor types
- Demonstrating how DISCOtech reveals tumor-specific vulnerabilities inaccessible through traditional genomics or transcriptomics
- Showcasing the translation from surfaceome discoveries to target candidates into differentiated antibody-based therapeutics with enhanced efficacy and safety profiles

Nikolai Slavov
Professor
Northeastern University

2.30 **Understanding Heterogeneity With Single-Cell Proteomics to Elucidate Drivers of Disease, Resistance & Immune Response**

- Utilizing single-cell technology to understand cell-to-cell protein variability, rare cell populations and functionally significant proteins
- Applying single-cell proteomics to predict therapeutic response, elucidate cell-specific disease mechanisms and inform patient stratification

Conference Day One
Wednesday, February 4, 2026

3.00 **Afternoon Break & Poster Session**

This is your opportunity to share your work with fellow members of the community, showcasing how your drug discovery breakthroughs were made possible with proteomics.

*Please visit website for more details.

Strategically Balancing Sensitivity, Coverage & Throughput of Proteomics Tools & Methodologies to Ascertain a Holistic Understanding of the Proteome

John Corradi
Director, Bioinformatics & Proteomics
Arvinas
Targeted Protein Degradation

3.45 **Proteomics Along the TPD Pipeline - Enabling Lead Optimization Through Clinical Biomarker Development**

- Exploring how proteomics is employed throughout the drug discovery process for targeted protein degradation
- Outlining how global proteomics helps guide medicinal chemistry and understand compound effects
- Discovering how targeted MS-based proteomics and alternative platforms can provide essential and exploratory clinical biomarkers

Stella Ritorto
Senior Director & Head of Mass Spectrometry
ProFound Therapeutics

4.15 **Round Table Discussion: Harmonizing Coverage, Specificity & Throughput to Enable Sensitive, Comprehensive Proteomics Analysis**

- Selecting appropriate instruments and methodologies and developing sensitive assays to enable accurate protein detection
- Standardizing analysis pipelines using protocols from academic consortia and biobanks to ensure reproducibility and scalability
- Combining in-house analysis, external capabilities, and AI platforms to quantify the proteome and draw meaningful biomedical conclusions from proteomics data sets

Michael Roehrl
Chair, Department of Pathology
Beth Israel Deaconess Medical Center

5.00 **Proteomics in Precision Medicine & Drug Development: From Biomarkers to Companion Diagnostics**

- Outlining the unique benefits of adopting proteomics in precision medicine
- Developing better biomarkers using insights generated from proteomics
- Exploring data that shows how proteomics can be used as companion diagnostics

5.30 **End of Conference Day One**

> "A valuable opportunity to network with leading proteomics experts, exchange ideas across diverse research areas, and stay current on emerging technologies driving the field"
>
> **Executive Director, Aethon Therapeutics**

Conference Day Two
Thursday, February 5, 2026

8.00 **Check In & Light Breakfast**

Satya Saxena
Director of Global Proteomics
Eisai

8.50 **Chair's Opening Remarks**

Revolutionizing Target Discovery & Screening With Insights From High Throughput Chemoproteomics Platforms to Expand the Druggable Proteome

Karsten Krug
Director, Head of Bioinformatics
Frontier Medicines
Covalency

9.00 **Leveraging the Unique Power of Chemoproteomics for Hit Identification & Screening to Transform Discovery of Therapeutic Candidates**

- Explore the Frontier Platform which combines chemoproteomics, covalent fragment-based discovery, and AI to access more than 90% of the proteome
- Discover how a custom-built covalent fragment library that leverages the concept of enantiomer pairs was used to reveal immediate SAR through enantiomer-specific hits, enabled by chemoproteomic screening in live cells capturing proteome-wide engagement signatures
- Presenting novel quality-control metrics for large-scale chemoproteomic screening of covalent enantiomer libraries, complementing compound purity checks and improving triage of true hits for downstream assays

Ansgar Brock
Associate Director
Novartis
Covalency

9.30 **Pocket Finding & Ligand Discovery by Chemoproteomics for Covalent Drug Discovery**

- Outlining how combining fully functionalized libraries, automated protein-level enrichment, and DIA-MS provides a robust high-throughput chemoproteomic platform for proteome-wide screening of libraries
- Discover how protein level data provides convincing information for the presence of ligandable sites
- Discuss how the data informs about preferred chemotypes of electrophilic warheads for covalent drug design

Katherine Donovan
Managing Director, Fischer Labs
Dana-Farber Cancer Institute

10.00 **Adopting Chemoproteomics Platforms to Inform Target Discovery & Drug Previously Undruggable Targets**

- Developing a robust, high-throughput chemoproteomics platform to identify novel binding pockets, facilitate efficient target discovery, and drug orphan receptors
- Characterizing ligandable sites and binding pockets to unlock a plethora of novel target sites for hard-to-drug proteins
- Discussing data showing the unique benefit of applying chemoproteomics to transform target discovery and maximize time and cost-efficiency of R&D

Antony Burton
Associate Director, Chemical Biology & Proteomics
Dunad Therapeutics
Covalency

10.30 **Chemoproteomics-Based Discovery of CNS-Penetrant Covalent Inhibitors**

- Effectively utilizing chemoproteomic platforms to triage hits and facilitate efficient hit-to-lead development
- Conducting high-throughput screening in physiological conditions to streamline translation
- Data to exemplify how chemoproteomics has enabled the detection and optimization of clinically successful therapeutic candidates

11.00 **Morning Break & Networking**

Conference Day Two
Thursday, February 5, 2026

Illuminating Post-Translational Modifications With Proteomics to Understand Disease Mechanisms & Inform Therapeutic Strategy

Ben Ruprecht
Director, Proteomics
Blueprint Medicines (a Sanofi company)
Targeted Protein Degradation

11.45 Quantitative Post-Translational Modifications (PTM) Omics to Support Drug Discovery

- Discussing optimized experimental PTM enrichment workflows for increased sensitivity and robustness
- Benchmarking novel mass spectrometers and proteomic data processing tools for enhanced coverage of the PTM-ome
- Sharing examples for the application of PTM data to guide decision-making in different stages of the drug discovery process

An Chi
Senior Director
Merck

12.15 Round Table Discussion: Unlocking Greater Understanding of the Proteome Through Accurate Analysis of Post-Translational Modifications

- Capturing rare PTMs including tyrosine phosphorylation, glycosylation, and ubiquitination
- Overcoming limitations of instrument sensitivity to detect PTMs from limited samples and draw meaningful biomedical conclusions
- Evaluating the importance and feasibility of analyzing PTMs and selecting the appropriate instruments and workflows to do so

1.00 Lunch Break & Networking

Defining Gold-Standard Data Analysis Methodologies & Utilizing AI Capabilities to Generate Unique Biomedical Insights From Large Proteomics Data Sets

Liang Xue
Director, Bioinformatics
Pfizer

2.00 Standardizing Proteomics Data Analysis & Selecting Appropriate Analysis Frameworks to Ensure Reproducibility & Statistical Accuracy

- Creating robust and reproducible data analysis methodologies to facilitate precise biomedical conclusions
- Developing consistent statistical and data normalization strategies to mitigate for missing data and variability across proteomics platforms
- Harmonizing assay design and sample prep to ensure compatibility with downstream analysis methods across *in vitro*, *in vivo*, and clinical models

2.30 Panel Discussion: Establishing a Consensus on Proteomics Methodologies & Data Sharing to Enable Reproducible Analysis & Reliable Interpretation of Data

- Defining robust, standardized proteomics methodologies, from sample collection and analysis to statistical protocols and generation of biomedical conclusions
- Developing a collaborative database to facilitate secure data visualization and sharing, maximizing the impact of available data
- Establishing collaborative projects amongst consortiums, academia, and industry to utilize existing datasets and generate a deeper understanding of proteomics to direct therapeutic development

An Chi
Senior Director
Merck

Harris Bell-Temin
Director, Proteomics
Johnson & Johnson

Nikolai Slavov
Professor
Northeastern University

Conference Day Two
Thursday, February 5, 2026

Joon Jung
Senior Vice President, Head of Data Science
Acrivon Therapeutics
Small molecules

3.15 **Acrivon's Generative Phosphoproteomics AP3 Platform Accelerates Pathway-Based Drug Design & Enables Rapid Clinical Translation**

- Discuss the development of a computational pipeline and supporting infrastructure to analyze large-scale phosphoproteomics datasets and systematically characterize drug-regulated signaling network dynamics
- Applying a proprietary generative AI model to predict kinase–substrate relationships, enabling deeper pathway interrogation
- Utilizing these approaches to define differentiated AP3 drug response profiles and facilitate the identification of predictive biomarkers to support patient stratification and translational applications

Morgan Stykel
Senior Scientist
Aquinnah Pharmaceuticals
Small molecules

3.45 **Leveraging Proteomics for Target Identification & Mechanistic Insights in Pre-Clinical Drug Discovery**

- Use of limited proteolysis to identify candidate target proteins for Aquinnah Pharmaceuticals' small molecule aimed at reducing tau pathology
- Confirmation of target using siRNA screening using in-house phenotypic assays
- Ongoing proteomic studies to define how the compound modulates target activity and its broader biological impact

Satya Saxena
Director of Global Proteomics
Eisai

4.15 **Chair's Closing Remarks**

End of 2nd Proteomics Based Drug Discovery Summit

> "This summit is a catalyst for innovation in proteomics-driven drug discovery. By bringing together thought leaders, it accelerates the translation of cutting-edge science into novel therapies"
>
> **Associate Director, Aethon Therapeutics**

Showcase Your Expertise

Proteomics Based Drug Discovery Summit
February 3-5, 2026 | Boston, MA

Demonstrate Your Proteomics Capabilities & Create New Connections With Industry Leaders

Biopharma is increasingly adopting proteomics to unlock undruggable targets, illuminate disease mechanisms and de-risk discovery pipelines.

If your capabilities include global, spatial, or single-cell proteomics, mass spectrometry, PTM analysis, data analysis, or assay development, get in touch to find out more about our bespoke partnership opportunities to help you achieve your commercial goals.

Exclusive Benefits Include:

Engage with the key players in proteomics

Build meaningful industry relationships with the decision makers driving biopharma's proteomics workflows

Own the spotlight as the leading proteomics expert

Demonstrate your proteomics instruments, exemplify your customer service skills and display your analysis protocols

Keep your finger on the pulse of proteomics

Gain first-hand insight into the challenges and priorities your target market is facing so you can efficiently deliver solutions

Seniority of Attendees



- C-Level Executive & President – 40%
- Director & Head – 32%
- Scientist – 21%
- Professor – 4%
- Other – 3%

Type of Companies Attending



- Drug Developers
- Academic & Others
- Service Providers

Statistics taken from Inaugural Proteomics Based Drug Discovery Summit

Get Involved



Molly Biggin
Business Development Manager
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Official Partners

Syncell

Syncell is a life science technology company at the forefront of developing tools for next-generation proteomics. Our pioneering Microscoop® technology enables the discovery of spatial protein constituents, making de novo subcellular spatial proteomics feasible for the first time. This groundbreaking technology can be applied to a broad range of biological problems, aiding in the understanding of molecular mechanisms, identifying novel disease biomarkers, and revealing new drug targets.

www.syncell.com

"As an expert at the intersection of proteomics and drug development, I see great value in exchanging insights on emerging technologies and translational strategies.

This summit offers a unique opportunity to stay informed the latest advances in technology and data integration and build relationships with peers to enable more effective therapeutic development"

Vice President, DISCO Pharmaceuticals

Get Involved



Molly Biggin
Business Development Manager
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Ready to Register?

3 Easy Ways to Book

www.proteomic-drug-discovery.com/take-part/register

Tel: +1 617 455 4188

Email: info@hansonwade.com

Illuminate the proteome with insightful data elucidating disease mechanisms to unlock previously undruggable targets

Optimize large-scale data analysis with standardized methodologies and computational tools to build efficient proteomics workflows

Collaborate with your fellow experts working in proteomics across multiple modalities to derisk your discovery pipeline

Drug Developer Pricing*	Register by Friday, October 31 & Save	On the Door Price
Conference + 2 Workshops	$3,297 **(Save $900)**	$4,197
Conference + 1 Workshop	$2,898 **(Save $700)**	$3,598
Conference Only	$2,499 **(Save $500)**	$2,999

Academic Pricing **	Register by Friday, October 31 & Save	On the Door Price
Conference + 2 Workshops	$2,697 **(Save $900)**	$3,597
Conference + 1 Workshop	$2,398 **(Save $700)**	$3,098
Conference Only	$2,099 **(Save $500)**	$2,599

Solution & Service Provider Pricing	Register by Friday, October 31 & Save	On the Door Price
Conference + 2 Workshops	$4,297 **(Save $900)**	$5,197
Conference + 1 Workshop	$3,798 **(Save $700)**	$4,498
Conference Only	$3,299 **(Save $500)**	$3,799

To qualify for the drug developer rate your company must have a public drug pipeline and not offer fee-based services. Please visit the website for full pricing options or email info@hansonwade.com

Do you work for a Not-for-Profit organization? Email us at info@hansonwade.com to inquire about attending

**To qualify for academic & research rate you must be full time academic. Please visit the website for full pricing options or email info@hansonwade.com

Team Discounts***

- **10% discount – 2 Attendees**
- **15% discount – 3 Attendees**
- **20% discount – 4+ Attendees**

***Please note that discounts are only valid when two or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com

Venue

Revere Hotel Boston Common
200 Stuart St, Boston, MA 02116, United States
www.reverehotel.com

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Ltd, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom